Blocking Connexin-43 may improve diabetic retinopathy, AMD
February 11th 2022Dr David S. Boyer describes how blocking Connexin-43 may improve the retinal vascular system function in patients with diabetes, potentially creating a future of oral medication for treatment of diabetic retinopathy and AMD.
BREAKING NEWS: Faricimab approved by U.S. FDA for treatment of wet AMD, DMO
January 29th 2022Genentech’s treatment of faricimab is the first and only FDA-approved medicine targeting two distinct pathways, angiopoietin (Ang)-2 and vascular endothelial growth factor (VEGF)-A, that often cause retinal diseases that may cause visual loss.
Luminopia’s VR headset for amblyopia therapy receives US FDA approval
October 23rd 2021The Luminopia One VR headset is indicated for improved visual acuity in children ages 4-7 with amblyopia, associated with anisometropia or mild strabismus, after receiving treatment instructions from a trained eye care professional.
OCULUS joins International Myopia Institute in mission to raise myopia awareness
August 11th 2021OCULUS has combined efforts with International Myopia Institute to raise awareness of myopia and drive scientific advancements to prevent sight-threatening complications and blindness, which may arise as a result.
Application for Genentech’s faricimab accepted by U.S. FDA for treatment of wet AMD and DMO
August 3rd 2021If approved, Genentech’s treatment of faricimab will be the first and only medicine targeting two distinct pathways, Ang-2 and VEGF-A, that often cause retinal diseases that may cause vision loss.